Precision therapeutics for genetically defined diseases
Joined October 2014
- Tweets 312
- Following 28
- Followers 1,616
- Likes 54
179 Photos and videos
Jun 12
We’re in Stockholm for #EHA2026 presenting updated data from our APEX trial in AdvSM as well as pathobiology data in AdvSM & preclinical data from our JAK2 V617F program. Read more here: bit.ly/43x57xT and find our posters & presentations here: bit.ly/4dGfBkx
3
88
May 30
Today we shared detailed clinical data and updates from our #GIST program being presented at #ASCO26.
Read the release: bit.ly/4uES49o and find the presentation here: bit.ly/4dGfBkx
1
2
171
May 28
We’re thrilled to share that the FDA has accepted our 2nd NDA this year! Our combo of bezuclastinib sunitinib for patients w/#GIST received Priority Review! We're deeply grateful to the patients, families, investigators & entire Cogent team. Read more: bit.ly/4va65vK
1
5
104
May 27
Join us for a fireside chat at the @Jefferies Global Healthcare conference in New York on June 3 at 11:05am ET. Register and listen to the webcast here. bit.ly/4wSfRnN #JefferiesHealthcare
75
May 14
We’re excited to present pivotal data from our APEX trial in #AdvSM & preclinical data from our emerging JAK2 V617F program at #EHA2026. We look forward to seeing you in Stockholm & connecting w/the hematology community! Find presentation details here bit.ly/4wqTG83.
1
5
1,018
Today we reported our first quarter 2026 financial results, highlighting continued momentum with bezuclastinib and our pipeline. Read more here: bit.ly/49c71am
2
135
Apr 22
We’re pleased to share that the Phase 3 PEAK trial has been selected for an oral presentation at #ASCO26. We’ll present data from our trial of bezuclastinib in combo w/sunitinib in patients w/GIST who have received prior treatment w/imatinib. Read more: bit.ly/3QzSaA4
2
224
Apr 17
At #AACR26 we’re presenting new preclinical data on our pan-KRAS inhibitor showcasing its selectivity profile which could lead to reduction in skin tox & from our brain penetrant ErbB2 inhibitor w/evidence of synergistic activity in combo w/HER2 ADCs. PR: bit.ly/4enZFnC
1
185
Today we announced we've submitted our second New Drug Application to the U.S. FDA with bezuclastinib; this one for #GIST! The NDA was submitted under the FDA’s RTOR program. It’s another important milestone for patients & for Cogent! Read our PR: bit.ly/48nRd3R
1
4
188
Mar 16
We're excited to share that the FDA has accepted our NDA for bezuclastinib in patients with NonAdvanced SM. We’re thankful to the patients, families, investigators & the entire Cogent team who made this significant achievement possible.
Read more: bit.ly/4cLC2Vi
1
176
Cogent is driven by our commitment 2 advancing therapies 4 those living w/#SystemicMastocytosis & #GIST. On #RareDiseaseDay , we wore stripes 2 raise awareness, show our support 4 the #SM & #GIST communities, & reflect on the people who inspire our work each day. #ShowYourStripes
2
134
Feb 28
We’re excited to be at the #AAAAI26 ! Today we’re presenting data from 6 bezuclastinib posters. Read the release bit.ly/4u27RiQ and find the posters here bit.ly/40x1vue. If you missed us at the poster sessions come see us in booth 917 in the Exhibit Hall!
3
431
Feb 17
Today we shared our 4QFY 2025 financial results and recent business highlights. We’re proud of our progress and look forward to what’s ahead. Read the full press release here: bit.ly/4kIQvDm
2
165
Jan 26
We’re pleased 2 announce that the FDA has granted Breakthrough Therapy Designation for bezuclastinib in combo w/sunitinib for patients w/Gastrointestinal Stromal Tumors #GIST who have received prior treatment w/imatinib. Learn more: bit.ly/4q50h3L #raredisease #NDA #RTOR
2
253
Jan 20
We’re pleased to announce that the FDA has agreed to accept our GIST NDA submission under their RTOR program. Read more here: bit.ly/3Nwf4H6
#NDA #GIST #RTOR
2
156
Jan 12
This morning, we announced our 2026 anticipated commercial and clinical milestones for bezuclastinib & our precision therapies portfolio. Read today’s release here: bit.ly/4jF4gTd and listen to tomorrow’s #JPM26 webcast here: bit.ly/3LqsK5S
2
356
Our CEO, Andrew Robbins, will present at #JPM26 on Tuesday, January 13th, at 8:15 am PT/11:15am ET. Tune in to the live webcast on our website here: investors.cogentbio.com/even…
1
177
30 Dec 2025
Today we announced our first New Drug Application with bezuclastinib for #NonAdvSM to the U.S. FDA. This is an important milestone for patients and Cogent, and we are thrilled to have taken this next step. Read more: bit.ly/45wNzmN
1
173